# US 2006/0079524 A1 · Amino substituted aryloxybenzylpiperidine derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0079524 A1
- Document ID: US20060079524A1
- Status: Published application
- Kind: A1
- Application number: 11/230,849
- Filed: 2005-09-20
- Published: 2006-04-13
- Earliest claimed: 2004-10-08
- Assignees: H. Lundbeck A/S
- Inventors: Mohammad Marzabadi; Chien-An Chen; Yu Jiang; Kai Lu; Kim Andersen
- Web page: https://patentgrep.com/patent/US20060079524A1

## CPC

- C07D 211/26: with hydrocarbon radicals, substituted by nitrogen atoms
- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

## Claims

### Claim 1

A compound having the structure:
wherein each X1, X2, X3, X4 and X5is independently CR1 or N, provided that if one X is N then the remaining X are each CR1;
wherein each Y1, Y2, Y3 and Y4 is independently CR7 or N, provided that if one Y is N then the remaining Y are each CR7;
wherein G is hydrogen or —C(O)D;
wherein D is
wherein Z is —N(R5)— or —O—;
wherein each A is independently H or straight chained or branched C1-C4 alkyl;
wherein each R1 is independently H, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 fluoroalkyl, straight chained or branched C1-C7 alkoxy, F, Cl, Br or I;
wherein R2 is H or straight chained or branched C1-C4 alkyl;
wherein R3 is H or straight chained or branched C1-C4 alkyl;
or wherein the R2 moiety, the nitrogen atom adjacent to the R2 moiety, the R3 moiety, and a bond formed between the R2 moiety and the R3 moiety form:
wherein R4 is straight chained or branched C1-C4 alkyl, straight chained or branched C1-C4 fluoroalkyl or F;
wherein R5 is H or straight chained or branched C1-C4 alkyl;
wherein each R6 is independently straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 fluoroalkyl, straight chained or branched C1-C7 alkoxy, F, Cl, Br or I;
wherein each R7 is independently H, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 fluoroalkyl, straight chained or branched C1-C7 alkoxy, F, Cl, Br or I;
wherein R8 is H, straight chained or branched C1-C4 alkyl, straight chained or branched C1-C4 fluoroalkyl or F;
wherein m is an integer from 0 to 4 inclusive;
wherein n is an integer from 0 to 2 inclusive;
wherein p is an integer from 0 to 4 inclusive;
wherein q is an integer from 0 to 3 inclusive;
wherein r is 1 or 2;
wherein s is an integer from 0 to 4 inclusive;
wherein t is an integer from 2 to 4 inclusive; and
wherein w is an integer from 1 to 5 inclusive;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, having the structure:

### Claim 3 (depends on 2)

The compound of claim 2, wherein m is 0 or 1, and R6 is methyl, F or Cl.

### Claim 4 (depends on 3)

The compound of claim 3, wherein each X1, X2, X3, X4 and X5 is CR1, and each Y1, Y2, Y3 and Y4 is CR7.

### Claim 5 (depends on 4)

The compound of claim 4, wherein each R1 is independently H, methyl, F or Cl, and each R7 is independently H, F or methyl.

### Claim 6 (depends on 5)

The compound of claim 5, wherein D is

### Claim 7 (depends on 6)

The compound of claim 6, wherein D is
and Z is —N(R5)—.

### Claim 8 (depends on 7)

The compound of claim 7, wherein t is 2 or 3 and R2 is H, methyl or ethyl.

### Claim 9 (depends on 6)

The compound of claim 6, wherein D is

### Claim 10 (depends on 9)

The compound of claim 9, wherein w is 1 or 2, and R3 is H, methyl or ethyl.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R2 is H, methyl or ethyl.

### Claim 12 (depends on 6)

The compound of claim 6, wherein the R2 moiety, the nitrogen atom adjacent to the R2 moiety, the R3 moiety, and a bond formed between the R2 moiety and the R3 moiety form:
and p is 0.

### Claim 13 (depends on 6)

The compound of claim 6, wherein the R2 moiety, the nitrogen atom adjacent to the R2 moiety, the R3 moiety, and a bond formed between the R2 moiety and the R3 moiety form:
and p is 0.

### Claim 14 (depends on 1)

The compound of claim 1, wherein G is hydrogen.

### Claim 15 (depends on 14)

The compound of claim 14, wherein m is 0 or 1 and R6 is methyl, F or Cl.

### Claim 16 (depends on 15)

The compound of claim 15, wherein each X1, X2, X3, X4 and X5 is CR1, and each Y1, Y2, Y3 and Y4 is CR7.

### Claim 17 (depends on 16)

The compound of claim 16, wherein each R1 is independently H, methyl, F or Cl; and each R7 is independently H, F or methyl.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1)

A process for making a pharmaceutical composition comprising admixing a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A method of treating a subject suffering from depression comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

### Claim 21 (depends on 1)

A method of treating a subject suffering from anxiety comprising administering to the subject a therapeutically effective amount of the compound of claim 1.
